Trials / Completed
CompletedNCT01767896
Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine
Phase III Study of ASP7374 -Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,020 (actual)
- Sponsor
- UMN Pharma Inc. · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (TIV) in elderly subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ASP7374 | subcutaneous (sc) |
| BIOLOGICAL | approved egg-derived TIV | subcutaneous (sc) |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2013-01-15
- Last updated
- 2017-09-29
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01767896. Inclusion in this directory is not an endorsement.